nevirapine has been researched along with Koch's Disease in 53 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We hypothesize that Nevirapine is a cheaper alternative that possesses equal efficacy as Efavirenz in HIV-Tuberculosis (TB) co-infected patients." | 9.24 | Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study. ( Dhooria, S; Gupta, K; Pandey, RM; Ranjan, S; Sinha, S; Tripathy, S, 2017) |
| "This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique." | 9.19 | Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014) |
| "In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs." | 9.17 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. ( Bastos, R; Baudin, E; Bhatt, N; Bonnet, M; Calmy, A; Ciaffi, L; Jani, I; Michon, C; Nunes, E; Rouzioux, C; Silva, C; Sobry, A; Taburet, AM, 2013) |
| "To describe the longitudinal changes in hepatic function among HIV-infected tuberculosis (TB) patients receiving once-daily nevirapine (NVP)- or efavirenz (EFV)-based antiretroviral treatment (ART) along with rifampin-containing anti-TB treatment." | 9.17 | Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy. ( Bhavani, PK; Chandrasekar, C; Hannah, E; Kumar, H; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Ramesh, C; Swaminathan, S; Tang, A; Wanke, C, 2013) |
| "Administration of rifampicin along with nevirapine reduces the plasma concentration of nevirapine in human immunodeficiency virus positive individuals with concomitant tuberculosis (HIV-TB patients)." | 9.17 | Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. ( Ahmad, H; Chandrashekhar, R; Dhooria, S; Ekka, M; Khan, NH; Kumar, S; Pandey, RM; Raghunandan, P; Ranjan, S; Rewari, BB; Samantaray, JC; Sharma, SK; Sinha, S; Velpandian, T; Venkatesh, S, 2013) |
| "Nevirapine (NVP) can be safely and effectively administered once-daily but has not been assessed in human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB)." | 9.15 | Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. ( Bhavani, PK; Dilip, M; Iliayas, S; Menon, PA; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Pooranagangadevi, NP; Ramachandran, R; Ramesh Kumar, S; Selvaraju, S; Swaminathan, S; Venkatesan, P, 2011) |
| "eighteen HIV-1/tuberculosis co-infected adults receiving rifampicin daily as part of anti-tuberculosis therapy were evenly randomized to nevirapine initiation by dose escalation (NVP200) or nevirapine initiation at 200 mg twice daily (NVP400)." | 9.15 | Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. ( Back, D; Boffito, M; Byakika-Kibwika, P; Coakley, P; Colebunders, R; Kalemeera, F; Khoo, S; Lamorde, M; Merry, C; Namakula, R; Okaba-Kayom, V; Ryan, M, 2011) |
| "Patients were divided into two groups: (1) patients receiving nevirapine-containing antiretroviral regimen (200 mg twice daily) and continuation phase rifampicin-containing tuberculosis therapy (n = 27) in whom blood samples were obtained before and not less than 14 days after they completed tuberculosis therapy; (2) patients without tuberculosis who were receiving a nevirapine-containing antiretroviral regimen for at least 3 weeks (n = 26)." | 9.14 | Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. ( Cohen, K; Elsherbiny, D; Jansson, B; McIlleron, H; Simonsson, US; Smith, P, 2009) |
| "We aim here to determine the appropriate dose of nevirapine (NVP) in Thai HIV-tuberculosis (TB)-coinfected patients receiving rifampicin." | 9.13 | Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. ( Avihingsanon, A; Burger, D; Chuchotaworn, C; Cooper, DA; Gorowara, M; Ishikawa, N; Kantipong, P; Manosuthi, W; Mitarai, S; Moolphate, S; Phanuphak, P; Ruxrungtham, K; Sakornjun, W; Yamada, N; Yanai, H, 2008) |
| " Standard ART includes either nevirapine or efavirenz, however the efficacy of these drugs is limited in patients receiving rifampin treatment for tuberculosis (TB)." | 8.90 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. ( Chen, HJ; Deng, M; Jiang, HY; Ruan, B; Yang, Y; Zhang, MN, 2014) |
| "We describe nevirapine and efavirenz exposure on and off tuberculosis treatment and consequences for virological efficacy and tolerance in patients included in the ANRS 12146/12214-CARINEMO trial." | 7.81 | Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship. ( Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; da Silva, C; Furlan, V; Grinsztejn, B; Meggi, B; Taburet, AM, 2015) |
| "Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 7.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
| "We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation." | 7.78 | Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation. ( Capparelli, E; Chokephaibulkit, K; Cressey, TR; Lapphra, K; Prasitsuebsai, W; Vanprapar, N, 2012) |
| "Nevirapine-based ART is an option for HIV-infected patients who receive rifampin in resource-limited countries or those who cannot tolerate efavirenz." | 7.76 | Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. ( Chimsuntorn, S; Eampokarap, B; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Tantanathip, P; Thongyen, S, 2010) |
| "Nevirapine (NVP) plasma levels are reduced in patients receiving rifampicin (RFM) for tuberculosis (TB) treatment." | 7.75 | Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. ( Bonkoungou, V; Carosi, G; Carvalho, AC; Dembele, M; Kouanda, S; Matteelli, A; Monno, L; Regazzi, M; Saleri, N; Sanou, MJ; Simporé, J; Villani, P, 2009) |
| "There is limited comparative data between efavirenz (EFV) 600 mg/day and nevirapine (NVP) 400 mg/day-based antiretroviral therapy (ART) among HIV-1 patients with tuberculosis (TB) and receiving rifampicin." | 7.74 | Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. ( Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Sungkanuparph, S, 2008) |
| "Seventy patients with human immunodeficiency virus (HIV) and tuberculosis coinfection who initiated nevirapine-based antiretroviral therapy and had trough nevirapine levels determined while receiving rifampicin were enrolled in a study." | 7.74 | Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. ( Inthong, Y; Likanonsakul, S; Manosuthi, W; Phoorisri, T; Prasithsirikul, W; Ruxrungtham, K; Sungkanuparph, S, 2007) |
| "We prospectively followed 27 HIV-infected adult Malawians after starting Triomune (a generic fixed drug combination of stavudine, lamivudine and nevirapine) in the second week of tuberculosis treatment." | 7.74 | Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. ( Beadsworth, M; Burger, DM; Kumwenda, JJ; Longwe, T; Mateyu, G; van Oosterhout, JJ; Zijlstra, EE, 2007) |
| "In countries with high numbers of HIV/tuberculosis coinfection nevirapine and rifampin are used extensively." | 7.73 | Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. ( Anekthananon, T; Autar, RS; Burger, DM; Cooper, DA; Lange, JM; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sankote, J; Sujaikaew, K; Wit, FW, 2005) |
| "To determine whether rifampicin reduces serum concentrations of nevirapine and whether nevirapine modifies serum concentrations of rifampicin, levels of these agents were determined at steady state by high-performance liquid chromatography in 10 HIV-infected patients with tuberculosis." | 7.71 | Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. ( Crespo, M; Falco, V; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Ruiz, I, 2001) |
| "Concomitant treatment of tuberculosis (TB) and HIV is recommended and improves outcomes." | 6.79 | Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. ( Dooley, KE; Karlsson, MO; Svensson, EM, 2014) |
| "Twenty-two children were treated for HIV/TB coinfection, 10 of whom were girls." | 6.77 | Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. ( Burger, DM; Chintu, C; Cook, A; Gibb, DM; McIlleron, H; Merry, C; Mulenga, V; Oudijk, JM; Walker, AS, 2012) |
| "Nevirapine Cmin was subtherapeutic (<3 mg/L) in six patients during antitubercular therapy (one of whom developed virological failure) and in none afterwards." | 5.35 | Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. ( Boulle, A; Cohen, K; Goemaere, E; Maartens, G; McIlleron, H; Smith, PJ; van Cutsem, G, 2008) |
| " We hypothesize that Nevirapine is a cheaper alternative that possesses equal efficacy as Efavirenz in HIV-Tuberculosis (TB) co-infected patients." | 5.24 | Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study. ( Dhooria, S; Gupta, K; Pandey, RM; Ranjan, S; Sinha, S; Tripathy, S, 2017) |
| "This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique." | 5.19 | Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014) |
| "In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs." | 5.17 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. ( Bastos, R; Baudin, E; Bhatt, N; Bonnet, M; Calmy, A; Ciaffi, L; Jani, I; Michon, C; Nunes, E; Rouzioux, C; Silva, C; Sobry, A; Taburet, AM, 2013) |
| "To describe the longitudinal changes in hepatic function among HIV-infected tuberculosis (TB) patients receiving once-daily nevirapine (NVP)- or efavirenz (EFV)-based antiretroviral treatment (ART) along with rifampin-containing anti-TB treatment." | 5.17 | Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy. ( Bhavani, PK; Chandrasekar, C; Hannah, E; Kumar, H; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Ramesh, C; Swaminathan, S; Tang, A; Wanke, C, 2013) |
| "Administration of rifampicin along with nevirapine reduces the plasma concentration of nevirapine in human immunodeficiency virus positive individuals with concomitant tuberculosis (HIV-TB patients)." | 5.17 | Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. ( Ahmad, H; Chandrashekhar, R; Dhooria, S; Ekka, M; Khan, NH; Kumar, S; Pandey, RM; Raghunandan, P; Ranjan, S; Rewari, BB; Samantaray, JC; Sharma, SK; Sinha, S; Velpandian, T; Venkatesh, S, 2013) |
| "eighteen HIV-1/tuberculosis co-infected adults receiving rifampicin daily as part of anti-tuberculosis therapy were evenly randomized to nevirapine initiation by dose escalation (NVP200) or nevirapine initiation at 200 mg twice daily (NVP400)." | 5.15 | Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. ( Back, D; Boffito, M; Byakika-Kibwika, P; Coakley, P; Colebunders, R; Kalemeera, F; Khoo, S; Lamorde, M; Merry, C; Namakula, R; Okaba-Kayom, V; Ryan, M, 2011) |
| "Nevirapine (NVP) can be safely and effectively administered once-daily but has not been assessed in human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB)." | 5.15 | Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. ( Bhavani, PK; Dilip, M; Iliayas, S; Menon, PA; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Pooranagangadevi, NP; Ramachandran, R; Ramesh Kumar, S; Selvaraju, S; Swaminathan, S; Venkatesan, P, 2011) |
| "To our knowledge, to date, no prospective, randomized, clinical trial has compared standard doses of efavirenz- and nevirapine-based antiretroviral therapy among patients with concurrent human immunodeficiency virus type 1 (HIV-1) infection and tuberculosis (TB) who are receiving rifampicin." | 5.14 | A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. ( Burapatarawong, S; Likanonsakul, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Prasithsirskul, W; Prommool, V; Ruxrungtham, K; Sungkanuparph, S; Tantanathip, P; Thawornwa, U; Thongyen, S, 2009) |
| "Patients were divided into two groups: (1) patients receiving nevirapine-containing antiretroviral regimen (200 mg twice daily) and continuation phase rifampicin-containing tuberculosis therapy (n = 27) in whom blood samples were obtained before and not less than 14 days after they completed tuberculosis therapy; (2) patients without tuberculosis who were receiving a nevirapine-containing antiretroviral regimen for at least 3 weeks (n = 26)." | 5.14 | Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. ( Cohen, K; Elsherbiny, D; Jansson, B; McIlleron, H; Simonsson, US; Smith, P, 2009) |
| "We aim here to determine the appropriate dose of nevirapine (NVP) in Thai HIV-tuberculosis (TB)-coinfected patients receiving rifampicin." | 5.13 | Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. ( Avihingsanon, A; Burger, D; Chuchotaworn, C; Cooper, DA; Gorowara, M; Ishikawa, N; Kantipong, P; Manosuthi, W; Mitarai, S; Moolphate, S; Phanuphak, P; Ruxrungtham, K; Sakornjun, W; Yamada, N; Yanai, H, 2008) |
| " Standard ART includes either nevirapine or efavirenz, however the efficacy of these drugs is limited in patients receiving rifampin treatment for tuberculosis (TB)." | 4.90 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. ( Chen, HJ; Deng, M; Jiang, HY; Ruan, B; Yang, Y; Zhang, MN, 2014) |
| "Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 3.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
| "We describe nevirapine and efavirenz exposure on and off tuberculosis treatment and consequences for virological efficacy and tolerance in patients included in the ANRS 12146/12214-CARINEMO trial." | 3.81 | Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship. ( Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; da Silva, C; Furlan, V; Grinsztejn, B; Meggi, B; Taburet, AM, 2015) |
| "We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation." | 3.78 | Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation. ( Capparelli, E; Chokephaibulkit, K; Cressey, TR; Lapphra, K; Prasitsuebsai, W; Vanprapar, N, 2012) |
| "To report on 1) clinical, immunological and virological outcomes and 2) safety among human immunodeficiency virus (HIV) infected patients with tuberculosis (TB) who received concurrent nevirapine (NVP) and rifampicin (RMP) based treatment." | 3.76 | Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi. ( Bauerfeind, A; Foncha, C; Harries, AD; Kwanjana, J; Manzi, M; Misinde, D; Moses, M; Mwagomba, B; Tayler-Smith, K; Zachariah, R, 2010) |
| "Nevirapine-based ART is an option for HIV-infected patients who receive rifampin in resource-limited countries or those who cannot tolerate efavirenz." | 3.76 | Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. ( Chimsuntorn, S; Eampokarap, B; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Tantanathip, P; Thongyen, S, 2010) |
| "Nevirapine (NVP) plasma levels are reduced in patients receiving rifampicin (RFM) for tuberculosis (TB) treatment." | 3.75 | Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. ( Bonkoungou, V; Carosi, G; Carvalho, AC; Dembele, M; Kouanda, S; Matteelli, A; Monno, L; Regazzi, M; Saleri, N; Sanou, MJ; Simporé, J; Villani, P, 2009) |
| "Seventy patients with human immunodeficiency virus (HIV) and tuberculosis coinfection who initiated nevirapine-based antiretroviral therapy and had trough nevirapine levels determined while receiving rifampicin were enrolled in a study." | 3.74 | Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. ( Inthong, Y; Likanonsakul, S; Manosuthi, W; Phoorisri, T; Prasithsirikul, W; Ruxrungtham, K; Sungkanuparph, S, 2007) |
| "We prospectively followed 27 HIV-infected adult Malawians after starting Triomune (a generic fixed drug combination of stavudine, lamivudine and nevirapine) in the second week of tuberculosis treatment." | 3.74 | Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. ( Beadsworth, M; Burger, DM; Kumwenda, JJ; Longwe, T; Mateyu, G; van Oosterhout, JJ; Zijlstra, EE, 2007) |
| "In this cohort study, virological outcomes were inferior when nevirapine-based antiretroviral therapy was commenced while taking antitubercular treatment (vs without concurrent tuberculosis) but comparable when starting efavirenz-based antiretroviral therapy (vs without concurrent tuberculosis) or when tuberculosis developed while taking established nevirapine- or efavirenz-based therapies." | 3.74 | Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. ( Abrahams, M; Boulle, A; Coetzee, D; Cohen, K; Goemaere, E; Hilderbrand, K; Maartens, G; Mathee, S; Van Cutsem, G, 2008) |
| "There is limited comparative data between efavirenz (EFV) 600 mg/day and nevirapine (NVP) 400 mg/day-based antiretroviral therapy (ART) among HIV-1 patients with tuberculosis (TB) and receiving rifampicin." | 3.74 | Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. ( Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Sungkanuparph, S, 2008) |
| "In countries with high numbers of HIV/tuberculosis coinfection nevirapine and rifampin are used extensively." | 3.73 | Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. ( Anekthananon, T; Autar, RS; Burger, DM; Cooper, DA; Lange, JM; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sankote, J; Sujaikaew, K; Wit, FW, 2005) |
| "To determine whether rifampicin reduces serum concentrations of nevirapine and whether nevirapine modifies serum concentrations of rifampicin, levels of these agents were determined at steady state by high-performance liquid chromatography in 10 HIV-infected patients with tuberculosis." | 3.71 | Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. ( Crespo, M; Falco, V; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Ruiz, I, 2001) |
| "Concomitant treatment of tuberculosis (TB) and HIV is recommended and improves outcomes." | 2.79 | Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. ( Dooley, KE; Karlsson, MO; Svensson, EM, 2014) |
| "Twenty-two children were treated for HIV/TB coinfection, 10 of whom were girls." | 2.77 | Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. ( Burger, DM; Chintu, C; Cook, A; Gibb, DM; McIlleron, H; Merry, C; Mulenga, V; Oudijk, JM; Walker, AS, 2012) |
| "Severe hyperbilirubinemia (grade 3 or 4) occurred in 7 patients (5." | 2.76 | Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen. ( Lueangniyomkul, A; Mankhatitham, W; Manosuthi, W, 2011) |
| "Liver diseases are common in patients with HIV due to viral hepatitis B and C co-infections, opportunistic infections or malignancies, antiretroviral drugs and drugs for opportunistic infections." | 1.35 | The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. ( Colebunders, R; Feld, J; Kambugu, A; Katabira, E; Katwere, M; Ocama, P; Opio, KC; Piloya, T; Ronald, A; Thomas, D, 2008) |
| "Nevirapine Cmin was subtherapeutic (<3 mg/L) in six patients during antitubercular therapy (one of whom developed virological failure) and in none afterwards." | 1.35 | Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. ( Boulle, A; Cohen, K; Goemaere, E; Maartens, G; McIlleron, H; Smith, PJ; van Cutsem, G, 2008) |
| " Our findings suggest that decreased bioavailability of nevirapine because of rifampicin coadministration could be overcome by increasing the dose of nevirapine from 200 to 300 mg twice daily without short-term adverse events." | 1.33 | Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. ( Hemanthkumar, AK; Kumaraswami, V; Narendran, G; Padmapriyadarsini, C; Raja, K; Rajasekaran, S; Ramachandran, G; Sathishnarayan, S; Sukumar, B; Swaminathan, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (45.28) | 29.6817 |
| 2010's | 28 (52.83) | 24.3611 |
| 2020's | 1 (1.89) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, D | 1 |
| Yogeeswari, P | 1 |
| Bhat, P | 1 |
| Thomas, A | 1 |
| Srividya, M | 1 |
| Sriram, D | 1 |
| Afrane, AKA | 1 |
| Goka, BQ | 1 |
| Renner, L | 1 |
| Yawson, AE | 1 |
| Alhassan, Y | 1 |
| Owiafe, SN | 1 |
| Agyeman, S | 1 |
| Sagoe, KWC | 1 |
| Kwara, A | 2 |
| McIlleron, H | 4 |
| Denti, P | 1 |
| Cohn, S | 1 |
| Mashabela, F | 1 |
| Hoffmann, JD | 1 |
| Shembe, S | 1 |
| Msandiwa, R | 1 |
| Wiesner, L | 1 |
| Velaphi, S | 1 |
| Lala, SG | 1 |
| Chaisson, RE | 1 |
| Martinson, N | 1 |
| Dooley, KE | 2 |
| Sinha, S | 2 |
| Gupta, K | 1 |
| Tripathy, S | 1 |
| Dhooria, S | 2 |
| Ranjan, S | 2 |
| Pandey, RM | 2 |
| Bonnet, M | 3 |
| Bhatt, N | 1 |
| Baudin, E | 3 |
| Silva, C | 2 |
| Michon, C | 1 |
| Taburet, AM | 3 |
| Ciaffi, L | 1 |
| Sobry, A | 1 |
| Bastos, R | 1 |
| Nunes, E | 1 |
| Rouzioux, C | 1 |
| Jani, I | 1 |
| Calmy, A | 1 |
| Maartens, G | 4 |
| Gupta-Wright, A | 1 |
| Wood, R | 1 |
| Bekker, LG | 1 |
| Lawn, SD | 1 |
| Takuva, S | 1 |
| Evans, D | 1 |
| Zuma, K | 1 |
| Okello, V | 1 |
| Louwagie, G | 1 |
| Pillay, P | 1 |
| Ford, N | 1 |
| Shubber, Z | 1 |
| Ferrand, RA | 1 |
| Padmapriyadarsini, C | 3 |
| Bhavani, PK | 2 |
| Tang, A | 1 |
| Kumar, H | 1 |
| Ponnuraja, C | 3 |
| Narendran, G | 3 |
| Hannah, E | 1 |
| Ramesh, C | 1 |
| Chandrasekar, C | 1 |
| Wanke, C | 1 |
| Swaminathan, S | 6 |
| Raghunandan, P | 1 |
| Chandrashekhar, R | 1 |
| Sharma, SK | 1 |
| Kumar, S | 1 |
| Ekka, M | 1 |
| Velpandian, T | 1 |
| Ahmad, H | 1 |
| Samantaray, JC | 1 |
| Venkatesh, S | 1 |
| Rewari, BB | 1 |
| Khan, NH | 1 |
| Ramachandran, G | 3 |
| Kumar, AK | 1 |
| Ramesh, K | 1 |
| Rajesh, L | 2 |
| Chandrasekharan, C | 1 |
| Bhatt, NB | 2 |
| Barau, C | 1 |
| Amin, A | 1 |
| Meggi, B | 2 |
| Furlan, V | 2 |
| Grinsztejn, B | 2 |
| Barrail-Tran, A | 2 |
| Jiang, HY | 1 |
| Zhang, MN | 1 |
| Chen, HJ | 1 |
| Yang, Y | 1 |
| Deng, M | 1 |
| Ruan, B | 1 |
| Svensson, EM | 1 |
| Karlsson, MO | 1 |
| da Silva, C | 1 |
| Sando, D | 1 |
| Spiegelman, D | 1 |
| Machumi, L | 1 |
| Mwanyika-Sando, M | 1 |
| Aris, E | 1 |
| Muya, A | 1 |
| Jackson, E | 1 |
| Baernighausen, T | 1 |
| Hertzmark, E | 1 |
| Chalamilla, G | 1 |
| Fawzi, W | 1 |
| van Griensven, J | 1 |
| Choun, K | 1 |
| Chim, B | 1 |
| Thai, S | 1 |
| Lorent, N | 1 |
| Lynen, L | 1 |
| Sathia, L | 1 |
| Obiorah, I | 1 |
| Taylor, G | 1 |
| Kon, O | 1 |
| O'Donoghue, M | 1 |
| Gibbins, S | 1 |
| Walsh, J | 1 |
| Winston, A | 1 |
| Avihingsanon, A | 1 |
| Manosuthi, W | 10 |
| Kantipong, P | 1 |
| Chuchotaworn, C | 1 |
| Moolphate, S | 1 |
| Sakornjun, W | 1 |
| Gorowara, M | 1 |
| Yamada, N | 1 |
| Yanai, H | 1 |
| Mitarai, S | 1 |
| Ishikawa, N | 1 |
| Cooper, DA | 2 |
| Phanuphak, P | 2 |
| Burger, D | 1 |
| Ruxrungtham, K | 5 |
| Boulle, A | 2 |
| Van Cutsem, G | 2 |
| Cohen, K | 3 |
| Hilderbrand, K | 1 |
| Mathee, S | 1 |
| Abrahams, M | 1 |
| Goemaere, E | 2 |
| Coetzee, D | 1 |
| Elsherbiny, D | 1 |
| Jansson, B | 1 |
| Smith, P | 1 |
| Simonsson, US | 1 |
| Tantanathip, P | 3 |
| Prasithisirikul, W | 1 |
| Likanonsakul, S | 5 |
| Sungkanuparph, S | 6 |
| Ocama, P | 1 |
| Katwere, M | 1 |
| Piloya, T | 1 |
| Feld, J | 1 |
| Opio, KC | 1 |
| Kambugu, A | 1 |
| Katabira, E | 1 |
| Thomas, D | 1 |
| Colebunders, R | 2 |
| Ronald, A | 1 |
| Lalloo, UG | 1 |
| Lueangniyomkul, A | 3 |
| Mankatitham, W | 2 |
| Prasithsirskul, W | 1 |
| Burapatarawong, S | 1 |
| Thongyen, S | 2 |
| Thawornwa, U | 1 |
| Prommool, V | 1 |
| Wilkinson, KA | 1 |
| Seldon, R | 1 |
| Meintjes, G | 1 |
| Rangaka, MX | 1 |
| Hanekom, WA | 1 |
| Wilkinson, RJ | 1 |
| Matteelli, A | 1 |
| Saleri, N | 1 |
| Villani, P | 1 |
| Bonkoungou, V | 1 |
| Carvalho, AC | 1 |
| Kouanda, S | 1 |
| Sanou, MJ | 1 |
| Simporé, J | 1 |
| Monno, L | 1 |
| Carosi, G | 1 |
| Regazzi, M | 1 |
| Dembele, M | 1 |
| Chang, SY | 1 |
| Lin, SW | 1 |
| Hung, CC | 1 |
| Karunaianantham, R | 1 |
| Narayanan, PR | 1 |
| Moses, M | 1 |
| Zachariah, R | 2 |
| Tayler-Smith, K | 1 |
| Misinde, D | 1 |
| Foncha, C | 1 |
| Manzi, M | 2 |
| Bauerfeind, A | 1 |
| Mwagomba, B | 1 |
| Kwanjana, J | 1 |
| Harries, AD | 2 |
| Disratthakit, A | 1 |
| Doi, N | 1 |
| Takenaga, M | 1 |
| Ohta, Y | 1 |
| Chimsuntorn, S | 2 |
| Eampokarap, B | 1 |
| Nilkamhang, S | 1 |
| Lamorde, M | 1 |
| Byakika-Kibwika, P | 1 |
| Okaba-Kayom, V | 1 |
| Ryan, M | 1 |
| Coakley, P | 1 |
| Boffito, M | 1 |
| Namakula, R | 1 |
| Kalemeera, F | 1 |
| Back, D | 1 |
| Khoo, S | 1 |
| Merry, C | 2 |
| Mankhatitham, W | 2 |
| Venkatesan, P | 1 |
| Ramesh Kumar, S | 1 |
| Iliayas, S | 1 |
| Menon, PA | 1 |
| Selvaraju, S | 1 |
| Pooranagangadevi, NP | 1 |
| Dilip, M | 1 |
| Ramachandran, R | 1 |
| Prasitsuebsai, W | 1 |
| Cressey, TR | 1 |
| Capparelli, E | 1 |
| Vanprapar, N | 1 |
| Lapphra, K | 1 |
| Chokephaibulkit, K | 1 |
| Luaengniyomkul, A | 1 |
| Oudijk, JM | 1 |
| Mulenga, V | 1 |
| Chintu, C | 1 |
| Walker, AS | 1 |
| Cook, A | 1 |
| Gibb, DM | 1 |
| Burger, DM | 3 |
| Uttayamakul, S | 1 |
| Wichukchinda, N | 1 |
| Shioda, T | 1 |
| Khusmith, S | 1 |
| Oliva, J | 1 |
| Moreno, S | 1 |
| Sanz, J | 1 |
| Ribera, E | 2 |
| Molina, JA | 1 |
| Rubio, R | 1 |
| Casas, E | 1 |
| Mariño, A | 1 |
| Teck, R | 1 |
| Ascurra, O | 1 |
| Gomani, P | 1 |
| Humblet, P | 1 |
| Nunn, P | 1 |
| Salaniponi, FM | 1 |
| Friedland, GH | 1 |
| Autar, RS | 1 |
| Wit, FW | 1 |
| Sankote, J | 1 |
| Mahanontharit, A | 1 |
| Anekthananon, T | 1 |
| Mootsikapun, P | 1 |
| Sujaikaew, K | 1 |
| Lange, JM | 1 |
| Hemanthkumar, AK | 1 |
| Rajasekaran, S | 1 |
| Sukumar, B | 1 |
| Sathishnarayan, S | 1 |
| Raja, K | 1 |
| Kumaraswami, V | 1 |
| Thakkinstian, A | 1 |
| Rattanasiri, S | 1 |
| Chaovavanich, A | 1 |
| Prasithsirikul, W | 2 |
| Inthong, Y | 1 |
| Phoorisri, T | 1 |
| Gupta, A | 1 |
| Nayak, U | 1 |
| Ram, M | 1 |
| Bhosale, R | 1 |
| Patil, S | 1 |
| Basavraj, A | 1 |
| Kakrani, A | 1 |
| Philip, S | 1 |
| Desai, D | 1 |
| Sastry, J | 1 |
| Bollinger, RC | 1 |
| van Oosterhout, JJ | 1 |
| Kumwenda, JJ | 1 |
| Beadsworth, M | 1 |
| Mateyu, G | 1 |
| Longwe, T | 1 |
| Zijlstra, EE | 1 |
| Smith, PJ | 1 |
| Pou, L | 1 |
| Lopez, RM | 1 |
| Crespo, M | 1 |
| Falco, V | 1 |
| Ocaña, I | 1 |
| Ruiz, I | 1 |
| Pahissa, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin in Antiretroviral Naive Patients Co-infected With HIV and Tuberculosis in India.[NCT01805258] | Phase 3 | 135 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Randomized Non-inferiority Trial Comparing the Nevirapine-based Antiretroviral Therapy Versus the Standard Efavirenz-based ART for the Treatment of HIV-TB Co-infected Patients on Rifampicin-based Therapy (ANRS 12146 CARINEMO)[NCT00495326] | Phase 2/Phase 3 | 570 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A Phase I, Open-label, Randomized Crossover Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Lopinavir/Ritonavir and Single-dose TMC207 in Healthy Subjects.[NCT00828529] | Phase 1 | 16 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| A Phase I, Open-label, Single-sequence Drug-drug Interaction Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Nevirapine and Single-dose TMC207 in HIV-1 Infected Subjects.[NCT00910806] | Phase 1 | 16 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| A 48 Week, Randomized, Open-label, 2 Arm Study to Compare the Efficacy, Safety and Tolerability of HAART Containing Nevirapine 400mg/Day Versus Nevirapine 600 mg/Day in HIV-1 Infected Patients Started at 2-6 Weeks After Initiating Rifampin Containing Anti[NCT00476853] | Phase 2 | 42 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Durability of Stavudine, Lamivudine and Nevirapine Among Advanced HIV-1 Infected Patients With/Without Prior Co-Administration of Rifampicin: A 144-Week Prospective Study[NCT00703898] | Phase 4 | 140 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin[NCT00483054] | Phase 3 | 142 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Comparison of Nevirapine Levels With and Without Dose Escalation in HIV-infected Patients Commencing Antiretroviral Therapy Who Are Also Receiving Rifampicin Based Anti-tuberculous Therapy[NCT00617643] | Phase 4 | 18 participants (Anticipated) | Interventional | 2008-05-31 | Completed | ||
| Evaluation of Safety and Efficacy of Two Different Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment in Patients With HIV-1 and Tuberculosis[NCT00332306] | Phase 3 | 180 participants (Anticipated) | Interventional | 2006-06-30 | Active, not recruiting | ||
| Pilot Evaluation of Pulmonary Tuberculosis Screening in Antenatal Clinics in Lusaka, Zambia[NCT02053129] | 5,033 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| Prevention of Maternal to Infant HIV Transmission in India[NCT00061321] | Phase 3 | 770 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for nevirapine and Koch's Disease
| Article | Year |
|---|---|
Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Treatment Outcome; | 2013 |
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines | 2014 |
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Child; Cyclopropanes; Drug Interactions; HIV In | 2010 |
Can we get more HIV-positive tuberculosis patients on antiretroviral treatment in a rural district of Malawi?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Drug Therapy, Combina | 2005 |
18 trials available for nevirapine and Koch's Disease
| Article | Year |
|---|---|
Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HI | 2017 |
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzo | 2013 |
Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymp | 2013 |
Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropa | 2013 |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; Half-Life; | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Ch | 2008 |
Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Infections; Hu | 2008 |
Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
Topics: Administration, Oral; Adult; Antibiotics, Antitubercular; Computer Simulation; Cross-Sectional Studi | 2009 |
A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2009 |
Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Didanosine; Dru | 2009 |
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.
Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Drug Interactions; Female; HIV Infections; HIV-1; Hum | 2011 |
Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
Topics: Adult; Alkynes; Antibiotics, Antitubercular; Benzoxazines; Chemical and Drug Induced Liver Injury; C | 2011 |
Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzo | 2011 |
Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Cholesterol, HDL; Coinfection; Cyclopropanes; Female; HIV | 2012 |
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
Topics: Anti-HIV Agents; Antibiotics, Antitubercular; Case-Control Studies; Child, Preschool; Coinfection; F | 2012 |
Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.
Topics: Adult; Alkynes; Analysis of Variance; Antiretroviral Therapy, Highly Active; Antitubercular Agents; | 2012 |
Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
Topics: Age Distribution; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Inci | 2007 |
Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
Topics: Age Distribution; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Inci | 2007 |
Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
Topics: Age Distribution; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Inci | 2007 |
Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
Topics: Age Distribution; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Inci | 2007 |
31 other studies available for nevirapine and Koch's Disease
| Article | Year |
|---|---|
Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Cell Line; HIV; HIV Infections; HIV Reverse Transcriptase; I | 2011 |
HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies; | 2021 |
Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Breast Feeding; Case-Control Studies; Drug Therapy, C | 2017 |
ART and tuberculosis: the final nail in nevirapine's coffin?
Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections | 2013 |
Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte | 2013 |
Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Eswatini; Female; Foll | 2013 |
Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genetic Association St | 2013 |
Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzo | 2015 |
Time trends of baseline demographics and clinical characteristics of HIV infected children enrolled in care and treatment service in Dar es Salaam, Tanzania.
Topics: Adolescent; Age Distribution; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Benzoxazines; CD | 2015 |
Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Cambodia; Drug Interactio | 2015 |
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzo | 2008 |
Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2008 |
The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.
Topics: Anti-HIV Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Comorbidity; Female; | 2008 |
Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas?
Topics: Alkynes; Anti-Bacterial Agents; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV | 2009 |
Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; CD4 Lym | 2009 |
Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; CD4 Lymphocyte Count; Female; Follow-Up Studies | 2009 |
Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infect | 2009 |
Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi.
Topics: Adolescent; Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Chemical and Drug Induced Liver Inj | 2010 |
Anti-tuberculosis activity and drug interaction with nevirapine of inhalable lipid microspheres containing rifampicin in murine model.
Topics: Administration, Intranasal; Animals; Antibiotics, Antitubercular; Drug Interactions; Female; Lipids; | 2010 |
Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte Count; Confide | 2010 |
Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.
Topics: Administration, Oral; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Child; Child, Presch | 2012 |
Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; | 2003 |
Meeting notes from the 3rd IAS Conference. Treating TB and HIV concurrently.
Topics: Brazil; Congresses as Topic; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Rifampin | 2005 |
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
Topics: Anti-Infective Agents; Antibiotics, Antitubercular; Female; HIV Infections; Humans; Male; Middle Age | 2005 |
Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Drug Administration Sched | 2006 |
Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Drug Interacti | 2006 |
Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combinati | 2007 |
Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Drug Administr | 2007 |
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
Topics: Adult; Antitubercular Agents; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; | 2008 |
Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymp | 2008 |
Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.
Topics: Anti-HIV Agents; Antibiotics, Antitubercular; Chromatography, High Pressure Liquid; Drug Interaction | 2001 |